DK1696898T3 - ZN2 + -CHELATING DESIGN-BASED SHORT-CHAIN FAT ACIDS AS AN UNKNOWN CLASS OF HISTONDEACETYLASE INHIBITORS - Google Patents

ZN2 + -CHELATING DESIGN-BASED SHORT-CHAIN FAT ACIDS AS AN UNKNOWN CLASS OF HISTONDEACETYLASE INHIBITORS Download PDF

Info

Publication number
DK1696898T3
DK1696898T3 DK04812666.8T DK04812666T DK1696898T3 DK 1696898 T3 DK1696898 T3 DK 1696898T3 DK 04812666 T DK04812666 T DK 04812666T DK 1696898 T3 DK1696898 T3 DK 1696898T3
Authority
DK
Denmark
Prior art keywords
phenyl
benzamide
hydroxy
compound
amino
Prior art date
Application number
DK04812666.8T
Other languages
Danish (da)
English (en)
Inventor
Ching-Shih Chen
Lu Qiang
Original Assignee
Univ Ohio State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio State Res Found filed Critical Univ Ohio State Res Found
Application granted granted Critical
Publication of DK1696898T3 publication Critical patent/DK1696898T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK04812666.8T 2003-12-02 2004-12-01 ZN2 + -CHELATING DESIGN-BASED SHORT-CHAIN FAT ACIDS AS AN UNKNOWN CLASS OF HISTONDEACETYLASE INHIBITORS DK1696898T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52634803P 2003-12-02 2003-12-02
PCT/US2004/040211 WO2005055928A2 (en) 2003-12-02 2004-12-01 Zn2+ -chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors

Publications (1)

Publication Number Publication Date
DK1696898T3 true DK1696898T3 (en) 2016-02-22

Family

ID=34676611

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04812666.8T DK1696898T3 (en) 2003-12-02 2004-12-01 ZN2 + -CHELATING DESIGN-BASED SHORT-CHAIN FAT ACIDS AS AN UNKNOWN CLASS OF HISTONDEACETYLASE INHIBITORS

Country Status (9)

Country Link
US (2) US9115090B2 (enExample)
EP (1) EP1696898B1 (enExample)
JP (2) JP5107579B2 (enExample)
AU (1) AU2004296764B2 (enExample)
CA (1) CA2552279C (enExample)
DK (1) DK1696898T3 (enExample)
ES (1) ES2562778T3 (enExample)
HU (1) HUE028490T2 (enExample)
WO (1) WO2005055928A2 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2005055928A2 (en) * 2003-12-02 2005-06-23 The Ohio State University Research Foundation Zn2+ -chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors
WO2006017214A2 (en) * 2004-07-12 2006-02-16 Merck & Co., Inc. Inhibitors of histone deacetylase
WO2006066133A2 (en) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1896436A2 (en) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
ZA200800901B (en) 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
CA2633010A1 (en) * 2005-12-19 2007-06-28 Methylgene Inc. Histone deacetylase inhibitors for enhancing activity of antifungal agents
EP1973872A4 (en) * 2006-12-19 2012-05-09 Methylgene Inc HISTONDEACETYLASE HEMMER AND PROPHARMAKA THEREOF
US8796330B2 (en) 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
CN101417967A (zh) * 2007-10-26 2009-04-29 浙江海正药业股份有限公司 组蛋白去乙酰酶抑制剂、其组合物及其应用
CA2735593C (en) 2008-09-03 2017-08-15 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
CN102300550B (zh) * 2008-12-01 2014-04-23 宝洁公司 香料体系
GB0903480D0 (en) * 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
KR20120031170A (ko) * 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
WO2011103563A1 (en) * 2010-02-22 2011-08-25 Arno Therapeutics, Inc Methods and compositions for inhibiting and preventing the growth of malignant mast cells
US20110212969A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011106627A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US20140107166A1 (en) * 2011-02-14 2014-04-17 Dana-Farber Cancer Institute, Inc. Histone deacetylase inhibitors and methods of use thereof
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
JP6250403B2 (ja) 2011-02-28 2017-12-20 バイオマリン ファーマシューティカル インク ヒストン脱アセチル化酵素阻害剤
WO2013041407A1 (en) * 2011-09-19 2013-03-28 Cellzome Ag Hydroxamic acids as hdac6 inhibitors
AU2012319188B2 (en) 2011-10-03 2016-11-24 Sloan-Kettering Institute For Cancer Research Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
WO2014164784A1 (en) * 2013-03-12 2014-10-09 Arno Therapeutics Hdac inhibitor polymorphic forms and methods of use
BR112015023399A8 (pt) 2013-03-15 2019-12-03 Biomarin Pharm Inc inibidores de hdac, seu uso e composição farmacêutica
MX368293B (es) 2013-11-20 2019-09-27 Ohio State Innovation Foundation Métodos para suprimir caquexia relacionada a cáncer.
WO2015100363A1 (en) 2013-12-23 2015-07-02 The Trustees Of Columbia University In The City Of New York Selective hdac6 inhibitors
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
EP3307746A1 (en) * 2015-05-18 2018-04-18 National and Kapodistrian Universty of Athens Autotaxin inhibitors and uses thereof
WO2017011552A1 (en) 2015-07-13 2017-01-19 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2017015451A1 (en) * 2015-07-22 2017-01-26 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US10301255B2 (en) 2015-07-22 2019-05-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10022342B2 (en) 2015-09-02 2018-07-17 Ohio State Innovation Foundation Methods and compositions for treating multiple myeloma
US10280175B2 (en) 2016-02-02 2019-05-07 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
MX384836B (es) 2016-03-07 2025-03-14 Enanta Pharm Inc Agentes antivirales contra la hepatitis b
EP3468561A4 (en) 2016-06-10 2019-12-04 Enanta Pharmaceuticals, Inc. ANTIVIRAL AGENTS AGAINST HEPATITIS B
WO2018223122A1 (en) * 2017-06-02 2018-12-06 Ohio State Innovation Foundation Hdac3-selective inhibitors
EA202090514A1 (ru) 2017-08-28 2020-06-24 Энанта Фармасьютикалс, Инк. Противовирусное средство против гепатита в
TW201936192A (zh) 2017-12-06 2019-09-16 美商因那塔製藥公司 B 型肝炎抗病毒試劑
US10428070B2 (en) 2017-12-06 2019-10-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2019130346A1 (en) * 2017-12-27 2019-07-04 K Syed Zameer Ahmed Novel phenolic compounds from nerium indicum with anti-breast cancer activity
WO2019143902A2 (en) 2018-01-22 2019-07-25 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2019191166A1 (en) 2018-03-29 2019-10-03 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
JP2022500466A (ja) 2018-09-21 2022-01-04 エナンタ ファーマシューティカルズ インコーポレイテッド 抗ウイルス剤としての官能化複素環
SG11202105007TA (en) 2018-11-21 2021-06-29 Enanta Pharm Inc Functionalized heterocycles as antiviral agents
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
EP4142733B1 (en) * 2020-04-30 2025-10-01 Great Novel Therapeutics Biotech & Medicals Corporation Histone deacetylase inhibitors for immunomodulation in tumor microenvironment
CN112225737B (zh) * 2020-12-11 2021-04-09 北京鑫开元医药科技有限公司 具有hdac抑制活性的化合物、制备方法、组合物及用途
CN112516142B (zh) * 2020-12-11 2021-10-15 北京华氏精恒医药科技有限公司 一种具有hdac抑制活性的药物组合物、制备方法及其用途
CN114539098B (zh) * 2022-02-26 2024-05-24 青岛大学 一种双功能hdac6抑制剂、合成方法及应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5668650A (en) * 1979-11-07 1981-06-09 Otsuka Pharmaceut Co Ltd Benzoic acid amide derivative
DE3607993A1 (de) 1986-03-11 1987-09-17 Basf Ag Verfahren zur herstellung von diaziridinen und produkte daraus
NZ219974A (en) * 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
EP0641204B1 (en) * 1992-05-20 2000-08-16 Merck & Co. Inc. 17-ethers and thioethers of 4-aza-steroids
AU668181B2 (en) * 1992-05-20 1996-04-26 Merck & Co., Inc. Ester derivatives of 4-aza-steroids
US5783593A (en) * 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
IT1283637B1 (it) * 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US5776888A (en) * 1997-02-07 1998-07-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6034584A (en) * 1997-08-06 2000-03-07 Allen-Bradley Company, Llc Arrangement for mechanically coupling an overload relay to a contactor
JP4405602B2 (ja) * 1998-04-16 2010-01-27 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ヒストン脱アセチル化酵素阻害剤
US6429213B1 (en) * 1998-06-17 2002-08-06 Bristol Myers Squibb Pharma Co Cyclic hydroxamic acids as metalloproteinase inhibitors
US6320078B1 (en) 1998-07-24 2001-11-20 Mitsui Chemicals, Inc. Method of producing benzamide derivatives
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
JP2001081031A (ja) * 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
KR20020060226A (ko) 1999-11-10 2002-07-16 로즈 암스트롱, 크리스틴 에이. 트러트웨인 배합 화학요법
DK1233958T3 (da) 1999-11-23 2011-10-17 Methylgene Inc Hæmmere af histondeacetylase
JP2003528072A (ja) * 2000-03-17 2003-09-24 ブリストル−マイヤーズ スクイブ ファーマ カンパニー マトリックスメタロプロテアーゼおよびＴＮＦ−αの阻害剤としての環状β−アミノ酸誘導体
WO2001070675A2 (en) 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP2083005A1 (en) * 2000-09-29 2009-07-29 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
US20020172967A1 (en) * 2001-02-13 2002-11-21 Gadek Thomas R. Identification of non-covalent complexes by mass spectrometry
WO2002074298A1 (en) * 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Il-6 production inhibitors
ITMI20011733A1 (it) * 2001-08-07 2003-02-07 Italfarmaco Spa Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
JP3681673B2 (ja) 2001-10-31 2005-08-10 Ｊｆｅ炉材株式会社 高炉樋用不定形耐火物
JP2003137866A (ja) * 2001-11-01 2003-05-14 Sankyo Co Ltd フェニレンジアミン誘導体
AU2003211362A1 (en) 2002-02-21 2003-09-09 Osaka Industrial Promotion Organization N-hydroxycarboxamide derivative
EP1490015B1 (en) * 2002-03-15 2009-09-23 Wayne State University Novel 2-amino-9-((2-hydroxymethyl) cyclopropylidenemethyl) purines as antiviral agents
US20030225054A1 (en) * 2002-06-03 2003-12-04 Jingwu Duan Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents
TW200426138A (en) 2002-12-10 2004-12-01 Hoffmann La Roche Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives, their manufacture and use as pharmaceutical agents
ITMI20030025A1 (it) * 2003-01-10 2004-07-11 Italfarmaco Spa Derivati dell'acido idrossammico ad attivita' antinfiammatoria.
CA2523413A1 (en) * 2003-04-25 2004-11-11 The Penn State Research Foundation Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
EP1660437B1 (en) * 2003-08-26 2008-10-15 Amorepacific Corporation Hydroxamic acid derivatives and the method for preparing thereof
JP4939941B2 (ja) * 2003-08-26 2012-05-30 株式會社アモーレパシフィック ヒドロキサム酸誘導体及びその製造方法
WO2005055928A2 (en) 2003-12-02 2005-06-23 The Ohio State University Research Foundation Zn2+ -chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors
SG155222A1 (en) * 2004-08-13 2009-09-30 Genentech Inc Thiazole based inhibitors of atp-utilizing enzymes

Also Published As

Publication number Publication date
JP2007519619A (ja) 2007-07-19
AU2004296764B2 (en) 2011-04-28
AU2004296764A1 (en) 2005-06-23
US9115090B2 (en) 2015-08-25
ES2562778T3 (es) 2016-03-08
WO2005055928A3 (en) 2005-10-06
CA2552279A1 (en) 2005-06-23
US20090137679A1 (en) 2009-05-28
JP2011190283A (ja) 2011-09-29
CA2552279C (en) 2014-07-15
WO2005055928A2 (en) 2005-06-23
JP5702681B2 (ja) 2015-04-15
US20070225373A1 (en) 2007-09-27
US8318808B2 (en) 2012-11-27
EP1696898B1 (en) 2015-11-18
JP5107579B2 (ja) 2012-12-26
EP1696898A2 (en) 2006-09-06
EP1696898A4 (en) 2010-07-14
HUE028490T2 (en) 2016-12-28

Similar Documents

Publication Publication Date Title
DK1696898T3 (en) ZN2 + -CHELATING DESIGN-BASED SHORT-CHAIN FAT ACIDS AS AN UNKNOWN CLASS OF HISTONDEACETYLASE INHIBITORS
JP4405602B2 (ja) ヒストン脱アセチル化酵素阻害剤
RU2364589C2 (ru) Ингибиторы гистондезацетилазы из новых производных бензамида с сильной дифференцировочной и антипролиферативной активностью
Wen et al. Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy
US7173060B2 (en) Oxime derivatives and their use as pharmaceutically active agents
US8466161B2 (en) Hydroxamate derivative, a production method for the same, and a pharmaceutical composition comprising the same
US11026910B2 (en) α- and γ-truxillic acid derivatives and pharmaceutical compositions thereof
CN112105602A (zh) 基于喹啉和异喹啉的hdac抑制剂及其使用方法
WO2013192165A2 (en) Compounds and methods for activating the apoptotic arm of the unfolded protein response
WO2008068170A1 (en) Hdac inhibitors
CN103848795A (zh) 一种l,2,5-噁二唑-2-氧化物组蛋白去乙酰化酶抑制剂及其制备方法和应用
Ren et al. Design, synthesis, and biological evaluation of oxazolidone derivatives as highly potent N-acylethanolamine acid amidase (NAAA) inhibitors
US8110577B2 (en) Histone deacetylase inhibitors
Zhou et al. Discovery of a tetrahydroisoquinoline-based HDAC inhibitor with improved plasma stability
KR101900574B1 (ko) 신규한 n-히드록시벤즈아미드 및 이의 용도
Mehndiratta et al. Indole-3-ethylsulfamoylphenylacrylamides with potent anti-proliferative and anti-angiogenic activities
US12234205B1 (en) Sulfonylhydrazide derivatives as anticancer agents
CN102020588B (zh) 具有组蛋白去乙酰化酶抑制活性的三环化合物、其制备方法及应用
Lu Potent short-chain fatty acid-based histone deacetylase inhibitors as anti-tumor agents
HK1160443A1 (en) Histone deacetylase inhibitors
HK1160443B (en) Histone deacetylase inhibitors